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ABSTRACT
BACKGROUND AND PURPOSE: The Analysis of Recanalization after Endovascular Treatment of Intracranial Aneurysm (ARETA) prospective
study aims to determine factors predicting recurrence after endovascular treatment for intracranial aneurysms. In this publication, we review
endovascular techniques and present the study population. Characteristics of treated and untreated unruptured aneurysms were analyzed.
MATERIALS ANDMETHODS: Sixteen neurointerventional departments prospectively enrolled patients treated for ruptured and unrup-
tured intracranial aneurysms between December 2013 and May 2015. Patient demographics, aneurysm characteristics, and endovascular
techniques were recorded.
RESULTS: A total of 1289 patients with 1761 intracranial aneurysms, 835 (47.4%) ruptured, were enrolled. Of these, 1359 intracranial
aneurysms were treated by endovascular means. Ruptured intracranial aneurysms were treated by coiling and balloon-assisted coiling in
97.8% of cases. In unruptured intracranial aneurysms, the rates of flow diversion, flow disruption, and stent-assisted coiling were 11.6%,
6.9%, and 7.8%, respectively. Rupture status and aneurysm location, neck diameter, and sac size significantly influenced the chosen
technique. Treated unruptured intracranial aneurysms, compared with untreated counterparts, had larger aneurysm sacs (7.6 4.0 versus
3.4 2.0 mm; P 0.001) and neck dimensions (4.1 2.2 versus 2.4 1.3 mm; P 0.001) andmore frequently an irregular form (84.6% versus
44.4%; P 0.001). Also, its location influenced whether an unruptured intracranial aneurysm was treated.
CONCLUSIONS: Our study provides an overview of current neurointerventional practice in the ARETA cohort. The technique choicewas
influenced by aneurysm morphology, location, and rupture status. Flow diversion, flow disruption, and stent-assisted coiling were com-
monly used in unruptured intracranial aneurysms, while most ruptured intracranial aneurysms were treated with coiling and balloon-
assisted coiling.
ABBREVIATIONS: BAC balloon-assisted coiling; IA intracranial aneurysm; RIA ruptured intracranial aneurysm; SAC stent-assisted coiling; UIA unrup-
tured intracranial aneurysm; WFNSWorld Federation of Neurosurgical Societies
Endovascular embolization is an accepted and, in many cases,the preferred technique for the treatment of ruptured (RIA)
and unruptured intracranial aneurysms (UIA). In large prospec-
tive multicenter studies, the last patients enrolled were in 2002 in
the International Subarachnoid Aneurysm Trial,1 in 2006 in the
Analysis of Treatment by Endovascular approach ofNonruptured
Aneurysms (ATENA),2 and in 2007 in the Clinical and Anatom-
ical Results in the Treatment of Ruptured Intracranial Aneurysms
(CLARITY) trials.3 While the results of these studies are not out-
dated, it remains unclear whether they continue to reflect current
neurointerventional practice, particularly in light of major tech-
nical advances that have become available during the past decade,
first and foremost the advent of flow diverters4-6 and intrasaccular
flow disrupters,7-13 which have broadened the spectrum of aneu-
rysms amenable to reconstructive endovascular treatment. Un-
fortunately, little is known regarding the use of these devices in
common neurointerventional practice. Furthermore, while the
“remodeling technique”14 (also known as balloon-assisted coiling
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[BAC]) and stent-assisted coiling (SAC),15 were already available in
the late 1990s and the early 2000s, respectively, it is probable that
these techniques are currently more widely applied than a decade
ago.
Different factors may influence the neurointerventionist’s
choice of materials for treatment of an intracranial aneurysm
(IA), for example, the aneurysm rupture status, its sac and neck
diameter, and location. More important, due to the relative ab-
sence of evidence-based guidelines, chosen techniques are guided
by personal preferences, resulting in disparate treatment prac-
tices. Other factors influencing these practices are regulatory
agencies by limiting the reimbursement of novel devices. Publica-
tions defining modern treatment strategies are thus rare.16
In this study, we report on the endovascularmodalities used to
treat RIA and UIA in the Analysis of Recanalization after Endo-
vascular Treatment of Intracranial Aneurysm (ARETA) study, a
large prospective, multicenter cohort study. Furthermore, we are
seeking to present the demographics of the study population and
to gain insight into current practices of neurointerventional an-
eurysm treatment.
MATERIALS AND METHODS
The ARETA Study Protocol
ARETAwas conceptualized to systematically evaluate factors that
affect aneurysm recanalization after endovascular treatment dur-
ing a follow-up of 12 months. The study was sponsored by the
FrenchMinistry ofHealth in a ProgrammeHospitalier deRecher-
che Clinique, No. 12–001–0372, and was registered on www.
clinicaltrials.gov (NCT01942512). ARETA received national reg-
ulatory authorizations: approval from the Reims Institutional
Review Board, the Consultative Committee of Information Pro-
cessing inHealth Care Research Program, and theNational Com-
mission for Data Processing and Freedom. The study objective
and its protocol with inclusion and exclusion criteria have previ-
ously been described.17
Patients were prospectively enrolled in 16 centers in France
between December 2013 and May 2015. Consecutive enrollment
was notmandatory. The following baseline patient characteristics
were reported by the participating study sites: age; sex; current or
previous use of cigarettes (including the number of pack-years for
current and previous smokers), alcohol, cannabis and other rec-
reational drugs; arterial hypertension (defined as blood pressure
140/90 mm Hg, based on medical history); hypercholesterol-
emia and hypertriglyceridemia; diabetes mellitus; Ehlers-Danlos
syndrome or other connective tissue diseases; polycystic kidney
disease; and familial history of IA. Furthermore, centers reported
the initial World Federation of Neurosurgical Societies (WFNS)
grade for patients with RIA and the preprocedural modified
Rankin Scale score (mRS) for patients with UIA.
Recorded aneurysm characteristics were aneurysm sac diam-
eter (including trichotomization into10, 10–25, and25mm);
neck size (wide-neck being defined as 4 mm); aneurysm loca-
tion (extradural ICA, intradural ICA, including the posterior
communicating artery, middle cerebral artery, anterior commu-
nicating/anterior cerebral artery, or vertebrobasilar artery; terri-
tory branch aneurysms were included in the respective category);
aneurysm rupture status (ruptured or unruptured); aneurysm
morphology (regular or irregular); and number of IAs (single or
multiple).
Treatment modalities were at the discretion of the treating
interventional neuroradiologist and categorized into coils, BAC,
SAC, flow diversion, intrasaccular flow-disruption, and parent
vessel sacrifice. The use of techniques like dualmicrocatheter coil-
ing, Y-stent placement, or double BAC did not represent an
exclusion criterion. Patients treated by these modalities were
grouped into the respective categories (for example, double
BAC was analyzed as BAC).
Notably, patients with UIAs who did not undergo endovascu-
lar treatment of at least 1 aneurysm, including patients who un-
derwent clipping, were not included in the ARETA study.
Data Management and Statistics
Participating centers reported patient, aneurysm, and treatment
characteristics on a standardized form. The centers also collected
preoperative DSA and immediate postoperative DSA and trans-
ferred the results in an anonymized form to Reims University
Hospital. Aneurysm characteristics and treatment modalities of
all patients were reviewed, checked for accuracy, and, if necessary,
revised by 2 neuroradiologists (M.G., S.S.) at the managing site.
Data management and statistical analysis were conducted by the
Department of Research and Public Health of Reims University
Hospital (C.B.). We applied descriptive statistics: Data are pre-
sented with mean and SD for quantitative variables and number
and percentage for qualitative variables. Comparisons among
groups were analyzed using a 2 or Student t test. No imputation
method was used for missing data. Statistical analysis was per-
formed using SAS (Version 9.4; SAS Institute, Cary, North Caro-
lina). A P value .05 was considered significant.
RESULTS
Population Characteristics
In total, 1289 patients with 1761 IA remained for analysis (Fig-
ure). Table 1 details the demographic aspects of the study popu-
lation. Of 1289 patients, 811 (62.9%) presented with at least 1
RIA. Multiple aneurysms (ie, 1) were detected in 319 patients
(24.7%); the maximum number of IAs in a single patient was 8.
Among the 811 patients presenting with RIAs, 808 had avail-
able data for a World Federation of Neurosurgical Societies score
at admission. Distribution of WFNS scores at admission was as
follows: I in 390 (48.3%), II in 171 (21.2%), III in 40 (5.0%), IV in
115 (14.2%), and V in 92 (11.4%) patients. Among the 478 pa-
tients presenting with UIAs, 467 had available data for pretreat-
ment mRS scores. The distribution of pretreatment mRS was as
follows: mRS 0 in 344 (73.7%), mRS 1 in 114 (24.4%), mRS 2 in 5
(1.1%), mRS 3 in 2 (0.4%), and mRS 4 in 2 (0.4%) patients.
Aneurysm Characteristics
Of 1761 observed IAs, 835 (47.4%) were ruptured and 926 (52.6%)
were unruptured. Mean aneurysm diameter was 6.1 3.6 mm:
1524 IAs (87.5%) had diameters10mm, 214 IAs (12.3%) had
diameters between 10 and 25 mm, and 4 IAs (0.2%) had diam-
eters of25mm. Themean aneurysm neck diameter was 3.2
1.8mm.Wide-neck aneurysms with a neck diameter of4mm
accounted for 486 IAs (28.3%). Irregular configurations were
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observed in 1022 IAs (60.4%). Locations of the IAs are shown
in Table 2.
Endovascular treatment was performed for 1359 of 1761 an-
eurysms (77.2%). Among treated aneurysms, 835 (61.4%) were
ruptured. More than 1 aneurysm was treated during 1 session in
67 patients (5.2%): 24 of 478 (5.0%) patients with UIAs and 43 of
811 (5.3%) patients with RIAs.
Locations of the treated IAs are shown in Table 2. Treated
aneurysms had a mean diameter of 6.8  3.5 mm. Diameters of
10 mm were seen in 1149 IAs (84.5%), 206 IAs (15.2%) had
diameters between 10 and 25mm, and 4 IAs (0.3%)had diameters
of 25 mm. The mean neck size was 3.5  1.8 mm. Wide-neck
accounted for 434 IAs (31.9%). Irregular shapes were found in
967 treated aneurysms (71.2%).
Comparison of Treated and Untreated Unruptured
Aneurysms
Of 926 UIAs, 524 (56.6%) were treated. Treated UIAs had signif-
icantly greater dimensions both of the aneurysm sac (7.6  4.0
versus 3.4  2.0 mm; P  0.001) and the aneurysm neck (4.1 
2.2 versus 2.4  1.3 mm; P  0.001) than UIAs that were left
untreated.Of note, 375 untreatedUIAs (97.9%)were significantly
smaller than 10mmversus 413 treatedUIAs (78.8%) (P 0.001),
and 311 untreated UIAs (81.2%) were significantly smaller than 5
mm versus 113 treated UIAs (21.6%) (P  0.001). Treatment
rates ofUIAs varied among aneurysm locations: Overall, 67.4%of
anterior cerebral artery/anterior communicating artery aneu-
rysms (124 of 184), 68.7% of intradural ICA aneurysms (202 of
294), 68.1% of vertebrobasilar aneurysms (47 of 69), 41.4% of
extradural ICA aneurysms (36 of 87), and 39.7% of MCA aneu-
rysms (115 of 290) were treated by endovascular means. UIAs of
the extradural ICA were significantly less frequently treated than
aneurysms in other locations (36 of 87
[41.4%] versus 488 of 837 [58.3%]; P
.002). Likewise, UIAs of the MCA were
less frequently treated endovascularly
than UIAs in other locations (115 of 290
[39.7%] versus 409 of 634 [64.4%]; P
0.001). Moreover, UIAs with irregular
configurations were significantly more
frequently treated than UIAs with regular
configurations (303 of 358 [84.6%] versus
221 of 498 [44.4%]; P  0.001). The 55
irregular untreated UIAs were signifi-
cantly smaller than their treated counter-
parts (4.6 2.4 versus 7.0 3.4mm, P
0.001).
Endovascular Techniques
Endovascular techniques that were ap-
plied are shown in Table 3. UIAs were
significantly more frequently treated
with intrasaccular flow disruption (36 of
524 [6.9%] versus 5 of 835 [0.6%];
P  0.001), flow diversion (61 of 524
[11.5%] versus 4 of 835 [0.5%]; P 
0.001), and SAC (41 of 524 [7.8%] ver-
sus 8 of 835 [1.0%]; P  0.001) than
RIAs. Altogether, these 3 techniques were used for 26.1% ofUIAs.
One giant UIA was treated with a detachable balloon for parent
vessel occlusion, and 1 RIA was treated by parent vessel occlusion
using coils. RIAs were more frequently treated by coiling (461 of
835 [55.2%] versus 189 of 524 [36.1%]; P 0.001) and BAC (356
of 835 [42.6%] versus 196 of 524 [37.4%];P .06) thanUIAs, but
the difference was not statistically significant for BAC. Of note,
97.8% (817 of 835) of RIAs were treated by coiling or BAC.
Treatment modalities varied depending on the aneurysm
sac dimensions (Table 4). Aneurysms of 10 mm were more
frequently treated with flow diverters than aneurysms 10
mm (30 of 210 [13.8%] versus 35 of 1149 [3.1%]; P  0.001).
However, 54.7% (35 of 64) of flow-diverting procedures were
performed for treatment of aneurysms of10mm. Aneurysms
of10 mmwere more frequently treated with standard coiling
than aneurysms of10 mm (569 of 1149 [49.5%] versus 81 of
210 [38.6%]; P  .003). An additional analysis, further divid-
ing small aneurysms (10 mm) into aneurysms of5 and5
mm, was conducted and is shown in On-line Table 1. Most
important, interclass differences with the fourth size category
did not change for most treatment modalities (ie, coiling, BAC,
flow diversion, SAC, and parent vessel occlusion) compared
with the initial analysis with 3 size categories (10, 10–25,
25 mm). The only new significant difference was found for
flow disruption (P  0.001), which is explained by the infre-
quent use of the Woven EndoBridge (WEB aneurysm emboli-
zation system; Sequent Medical, Aliso Viejo, California) for
aneurysms of5 mm (2 of 399 [0.5%] versus 39 of 960 [4.1%];
P  0.001).
Treatment modalities also varied depending on the aneurysm
neck diameter (Table 5). Stent-assisted coiling, intrasaccular flow
FIGURE Flow chart of the study population. “Treatment failure” refers to an endovascular treat-
ment attempt that was aborted before a device was implanted.
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disrupters, and flow diverters were significantly more frequently
deployed in wide-neck aneurysms (32 of 434 [7.4%] versus 17 of
925 [1.8%]; P  0.001; 36 of 434 [8.3%] versus 5 of 925 [0.5%];
P  0.001; and 48 of 434 [11.1%] versus 17 of 925 [1.8%]; P 
0.001, respectively) than in narrow-neck IAs. Simple coiling was
significantlymore frequently used in narrow-neck IAs (511 of 925
[55.2%] versus 139 of 434 [32.0%]; P 0.001). Most interesting,
BAC was not used more frequently in wide-neck than in narrow-
neck aneurysms (177 of 434 wide-neck [40.8%] versus 375 of 925
narrow-neck IAs [40.6%]; P .93).
Aneurysm location affected the chosen treatment technique,
as shown in On-line Table 2. Notably, BAC was performed more
often for aneurysms of the intradural segment of the ICA than in
other aneurysm locations (204 of 438 [46.6%] versus 348 of 921
[37.8%]; P  .002). Conversely, flow diverters were deployed
more often in aneurysms of the intra- and extradural ICA than in
other aneurysm locations (41 of 438 [9.4%] versus 24 of 921
[2.6%]; P 0.001; and 15 of 37 [40.5%] versus 50 of 1322 [3.8%];
P  0.001, respectively). Also, SAC was used more often for ex-
tradural ICA aneurysms (6 of 37 [16.2%] versus 43 of 1322
[3.2%]; P .002). Furthermore, these extradural ICA aneurysms
were less frequently treated by standard coiling than IAs in other
locations (7 of 37 [18.9%] versus 643 of 1322 [48.6%];P 0.001).
Intra-aneurysmal flow disruption was used more often in
MCA and vertebrobasilar aneurysms than in other aneurysm
locations (19 of 283 [6.7%] versus 22 of 1076 [2.0%]; P 
0.001; and 7 of 104 [6.7%] versus 34 of 1255 [2.7%]; P  .03,
respectively).
DISCUSSION
Relevance of Flow Diversion, Intrasaccular Flow
Disruption, and Stent-Assisted Coiling
In ARETA, 11.6% of UIAs were treated by flow diversion, repre-
senting a significant proportion in this cohort. The US FDA ap-
proved the use of flowdiverters for patients with unruptured large
or giant wide-neck intracranial aneurysms in the ICA from the
petrous to the superior hypophyseal segments.18 The ARETA re-
sults are in line with current recommendations because flow di-
verters were used for wide-neck large and giant aneurysms at a
proportionally higher rate than for small and narrow-neck aneu-
rysms. Flow diverters were also used more frequently in aneu-
rysms of the intradural (9.4%) and extradural (40.5%) ICA.How-
ever, the extension of treatment indications to ruptured, small,
narrow-neck, or distal bifurcation aneurysms is increasingly re-
ported by some groups.19 Of note, in the present study, 53.8% of
flow diverters were used in aneurysms of10 mm, and 26.2% of
aneurysms treated with a flow diverter had a neck diameter of4
mm. A limited number of flow-diverting stents were also used for
the treatment of MCA and anterior communicating artery aneu-
rysms, a treatment concept that is currently under discussion.20,21
These numbers thus reflect a flexible application of current rec-
ommendations for the use of flow diversion if judged necessary by
the interventionist. Because an endoluminal implant is left in
place, dual antiplatelet therapy is usually necessary and the aneu-
rysm is at least temporarily left circulating (if no coils are added
during the procedure). Flow diverters were thus very rarely used
in RIAs (4 of 835 ruptured aneurysms [0.5%]); however, these
results may be biased by the exclusion of dissecting, fusiform, and
blisterlike aneurysms, where flow diversion is sometimes the only
treatment option when parent vessel sacrifice is not possible.22,23
Table 1: Demographic characteristics of 1289 patients
Variables
Female (No.) (%) 866 (67.2%)
Age (mean) 54.1 12.7 years
Single IA (No.) (%) 970 (75.3%)
Multiple IAs (No.) (%) 319 (24.7%)
2 IAs (No.) (%) 214 (67.1%)
3 IAs (No.) (%) 73 (22.9%)
4 IAs (No.) (%) 23 (7.2%)
5 IAs (No.) (%) 5 (1.6%)
6 IAs (No.) (%) 2 (0.6%)
7 IAs (No.) (%) 1 (0.3%)
8 IAs (No.) (%) 1 (0.3%)
Tobacco (No.) (%)a 768 (60.4%)
Active smoking (No.) (%)b 559/762 (73.4%)
Pack-years (mean)c 26.0 21.0
Regular alcohol consumption (No.) (%)d 255 (20.2%)
Cannabis use (No.) (%)e 45 (3.6%)
Other recreational drugs (No.) (%)d 15 (1.2%)
Hypertension (No.) (%)f 462 (36.1%)
With treatment (No.) (%)g 363/449 (80.9%)
Normalized blood pressure (No.) (%)h 304/429 (70.9%)
Dyslipidemia (No.) (%)i 226 (17.8%)
Hypercholesterolemia (No.) (%)j 195/207 (94.2%)
Hypertriglyceridemia (No.) (%)k 47/198 (23.7%)
With treatment (No.) (%)l 151/206 (73.3%)
Family history of IA (No.) (%)m 90 (7.2%)
Diabetes mellitus (No.) (%)f 63 (4.9%)
Dietary treatment onlyn 17/60 (28.3%)
Oral antidiabetic treatmento 40/62 (64.5%)
Insulin treatmentp 9/61 (14.8%)
Polycystic kidney disease (No.) (%)q 17 (1.3%)
Connective tissue disease (No.) (%)f 1 (0.1%)
a The following are missing data: 17 (1.3%).
b 6 (0.8%).
c 120 (15.6%).
d 24 (1.9%).
e 22 (1.7%).
f 9 (0.7%).
g 13 (2.8%).
h 33 (7.1%).
i 16 (1.2%).
j 19 (8.4%).
k 28 (12.4%).
l 20 (8.8%).
m 30 (2.3%).
n 3 (4.8%).
o 1 (1.6%).
p 2 (3.2%).
q 8 (0.6%).
Table 2: All aneurysms in the study collective and treated
aneurysms
Location
All
Aneurysmsa
Treated
Aneurysms
No. % No. %
ACA/AcomA 557 31.7 497 36.6
MCA 458 26.0 283 20.8
Intradural ICA 530 30.1 438 32.2
Extradural ICA 88 5.0 37 2.7
Vertebrobasilar 126 7.2 104 7.6
Total 1751 100 1359 100
Note:—ACA indicates anterior cerebral artery; AcomA, anterior communicating
artery.
a Two missing data.
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Intrasaccular flow disruption by the WEB device was used to
treat 3.0% of patients. This device was introduced in 2011, pri-
marily for treatment of complex wide-neck bifurcation aneu-
rysms of the MCA and basilar artery in particular.7-13 If we
grouped these aneurysms, 6.7% of both MCA and basilar artery
aneurysms were treated by this technique; 87.8% of WEB devices
were used in wide-neck aneurysms with neck diameters of 4
mm. In ARETA, intrasaccular flow disruption was often used in
UIAs (6.9% were treated by the WEB) and only in 0.6% of RIAs.
This may be because a wide range of WEB devices suitable for
various aneurysm configurations were not permanently available
in all departments; furthermore, the learning curve in WEB ap-
plicationmight be a limiting factor as well as a possible reluctance
to use this novel device in a ruptured aneurysm.Whereas the current
literature indicates that itmay be safe and effective to treat RIAswith
flow disrupters24—particularly because postinterventional anti-
platelet therapy is not imperative—large prospective controlled data
are not available and are subject to the CLinical Assessment ofWEB
Device in Ruptured aneurYSms (CLARYS) study, which recently
completed recruitment (NCT02687607: www.clinicaltrials.gov).
In the ARETA study, SAC was used in 3.6% of all aneu-
rysms. The use of dedicated self-expanding endoluminal de-
vices for SAC was first reported in 200215 and is now a standard
technique. SAC was primarily designed for the treatment of
unruptured wide-neck aneurysms, and in ARETA, it was used
in 7.8% of these aneurysms: Wide-neck aneurysms accounted
for 65.3% of SAC procedures. Stents usually necessitate a dual-
antiplatelet regimen and are associated with a higher compli-
cation rate in RIAs compared with UIAs.25 Conversely, only 8
patients (1%) with RIAs were treated with stent assistance;
moreover, it is not clear in howmany of these patients SAC was
used as a rescue treatment.
Overall, our study confirms that in patients presenting with a
ruptured saccular aneurysm, flow diversion, flow disruption, and
SAC currently play a minor role, given that 97.8% of RIAs were
amenable to treatment with simple coiling or BAC in our study.
Balloon-Assisted Coiling
BAC, also known as a remodeling technique, was used in 40.6%of
aneurysms in the present series (42.6% of RIAs and 37.4% of
UIAs). Since its initial description by Moret et al14 in 1997, BAC
has emerged as a standard treatment option. Apart from the abil-
ity to treat wide-neck aneurysms and offer improved immediate
and follow-up anatomic results,26 it has 2 additional potential
advantages over simple coiling, with a similar safety profile26: 1)
The microcatheter is stabilized during embolization, making it
easier to maintain access; and 2) in case of aneurysm perforation
during coiling, the balloon can be inflated while detaching several
coils to immediately protect and seal the rupture site. These po-
tential advantages are also reflected by the fact that BAC was not
more frequently used for the treatment of wide-neck than nar-
row-neck aneurysms in the present study. Aneurysm location in-
Table 3: Techniques used for embolization of ruptured and unruptured aneurysms
Treatment Modality
All IAs RIAs UIAs
P ValueNo. % No. % No. %
Coiling alone 650 47.8 461 55.2 189 36.1 0.001
Balloon-assisted coiling 552 40.6 356 42.6 196 37.4 .06
Stent-assisted coiling 49 3.6 8 1.0 41 7.8 0.001
Flow diversiona 65 4.8 4 0.5 61 11.6 0.001
Flow disruptionb 41 3.0 5 0.6 36 6.9 0.001
Parent vessel occlusion 2 0.2 1 0.1 1 0.2 .74
Total 1359 100 835 100 524 100
a Thirty aneurysms were treated in conjunction with coils.
b Two aneurysms were treated in conjunction with coils; 3 aneurysms, in conjunction with a remodeling balloon; and 1 aneurysm, with an ancillary stent.
Table 4: Treatment modality with regard to aneurysm sac diameter
Treatment Modality
All IAs <10 mm 10–25 mm >25 mm
P ValueNo. % No. % No. % No. %
Coiling alone 650 47.8 569 49.5 81 39.3 0 0 .003
Balloon-assisted coiling 552 40.6 472 41.1 80 38.8 0 0 .24
Stent-assisted coiling 49 3.6 37 3.2 12 5.8 0 0 .20
Flow diversion 65 4.8 35 3.1 27 13.1 3 75.0 0.001
Flow disruption 41 3.0 35 3.1 6 2.9 0 0 .93
Parent vessel occlusion 2 0.2 1 0.1 0 0 1 25.0 .006
Total 1359 100 1149 100 206 100 4 100
Table 5: Treatment modality with regard to aneurysm neck diameter
Treatment Modality
All IAs <4 mm ≥4 mm
P ValueNo. % No. % No. %
Coiling alone 650 47.8 511 55.2 139 32.0 0.001
Balloon-assisted coiling 552 40.6 375 40.5 177 40.8 .93
Stent-assisted coiling 49 3.6 17 1.8 32 7.4 0.001
Flow diversion 65 4.8 17 1.8 48 11.1 0.001
Flow disruption 41 3.0 5 0.5 36 8.3 0.001
Parent vessel occlusion 2 0.2 0 0 2 0.5 .10
Total 1359 100 925 100 434 100
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fluenced the frequency of BAC: Notably, it was used more often
for aneurysms of the intradural ICA (ie, posterior communicating
artery and paraophthalmic aneurysms).
InCLARITY, BACwas used in 20.5%of cases (versus 40.6% in
the present cohort); our study confirms the wider application of
BAC in cases of RIAs. The rationale behind this development is
likely linked to the increased risk of perforation in RIAs.3,27While
the rates of BAC between ARETA and ATENA for UIAs are com-
parable (37.3% in ATENA versus 37.4% in the present series), we
observed a decline in simple coiling approaches (54.5% in
ATENA versus 36.1% in ARETA).2 Flow diversion, flow dis-
ruption, and SAC were used in 26.2% of UIAs in the present
series, whereas neither flowdiversionnor intrasaccular flowdisrup-
tionwas available during the recruitment period of ATENA; 7.8%of
patients were treated by SAC in that study. Our results indicate that
treatment modalities of UIAs are currently shifting toward more
complex and novel approaches, away from the simple coiling
technique.
Comparison of Treated and Untreated Unruptured
Aneurysms
The rupture risk of UIAs depends on aneurysm size, location, and
shape and is generally low, especially in small aneurysms.28,29 Pre-
ventive treatment is generally justified if the benefit of treatment
outweighs the anticipated treatment risks. Therefore, it is not sur-
prising that untreated UIAs in ARETA were smaller than treated
counterparts and presented less frequently with an irregular form.
Furthermore, extradural ICA aneurysms, in which subarachnoid
hemorrhage is usually not a concern, were less frequently treated
thanUIAs of the anterior cerebral artery/anterior communicating
artery, the intradural ICA segment (which included the posterior
communicating artery in this study), and the vertebrobasilar ter-
ritory. Also, unruptured MCA aneurysms were less frequently
treated than UIAs in other locations, which may be because they
are less likely to rupture.28
Limitations of the Study
Our study has limitations. Because patients who underwent clip-
ping were not included in the study, a selection bias may exist, in
particular with MCA aneurysms in which clipping is still widely
used.However, endovascular treatment is currently the treatment
of choice for RIAs and UIAs in many institutions. Another limi-
tation is that consecutive enrollment of all patients treated in 1
center was not mandatory for the participation in the study. Be-
cause the study inclusion period ended in 2015, modifications of
the current practice with an even broader implementation of
novel techniques are probable, particularly intrasaccular flow dis-
ruption. The low percentage of novel techniques could also be
partly explained by regulatory mechanisms because during the
study period, there was no reimbursement for intrasaccular flow
disrupters or intravascular flow diverters and limited reimburse-
ment for conventional microstents by the French Health Insur-
ance (whereas the devices are, in case of nonreimbursement, paid
for by the hospital itself).Moreover, there is certainly a variance of
technical approaches among the participating centers. Another
limitation is that only the aneurysm rupture status was assessed at
inclusion into the ARETA cohort and compressive symptoms
were not evaluated. Our observations of the characteristics of
treated and untreated UIAs must be viewed with caution because
this study did not focus on the natural course of UIAs and there
was no prospective observation of rupture risk. Finally, this article
does not present clinical or anatomic outcome data, which will be
the subject of future publications.
CONCLUSIONS
Our study presents the demographics of the patient collective of
the ARETA study and provides a representative overview of cur-
rent endovascular treatment strategies for RIAs and UIAs. The
technique choice was influenced by the rupture status of the an-
eurysm, sac size, neck diameter, and location. While the evolving
techniques of flow diversion, intrasaccular flow disruption, and
stent-assisted coiling were deployed in a significant proportion of
UIAs, most RIAs were treated with simple coiling and balloon-
assisted coiling. When we compared the present study collective
with previously published series, shifting treatment regimens to-
ward more advanced techniques—away from simple coiling—
was observed. Moreover, we observed an influence of size, loca-
tion, and form on the decision of whether to treat UIAs.
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